Predictive Oncology’s (NASDAQ: POAI) flagship
subsidiary TumorGenesis is making strides in the identification and separation
of cancer-related biomarkers in an effort to quicken the development of new,
effective therapeutics. TumorGenesis is currently utilizing a new trend in
cancer research that leverages patient-derived xenografts (“PDx”). A recent
article discussing the company reads, “Science has shifted to these much more
accurate PDx models: A cancer patient’s tumor cells are implanted into an
alternate environment to simulate the natural development of the tumor. By
‘fooling the tumor’ with an imitative environment, new drugs are able to be
tested and potentially approved — all without subjecting cancer patients to
aggressive, potentially ineffective drugs. The cancer cells are tricked into
thinking they’re still multiplying inside the patient, which makes the tumor
behave as it would normally — revealing more precise cancer biomarkers.
TumorGenesis’ unique research approach benefits from the parent company’s
enormous database of tumor drug-response profiles and artificial
intelligence-driven predictive modeling capabilities. . . . TumorGenesis has
developed its proprietary methodology using PDx to culture tumor cells in vivo
(i.e. in living organisms). These cell models can be then tested repeatedly for
various new drugs to establish personalized therapeutics. This patient-specific
data is revolutionizing the way cancer is treated today, and POAI, through its
strategic subsidiary arms, poses an attractive option for investors looking to
invest in the cancer treatment of tomorrow.”
To view the full article, visit http://ibn.fm/eFafn
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five
segments (domestic, international, clinical, CRO and D-CHIP), which contain
four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe.
Helomics applies artificial intelligence to its rich data gathered from patient
tumors to both personalize cancer therapies for patients and drive the
development of new targeted therapies in collaborations with pharmaceutical
companies. Helomics’ CLIA-certified lab provides clinical testing that assists
oncologists in individualizing patient-treatment decisions by providing an
evidence-based road map for therapy. In addition to its proprietary
precision-oncology platform, Helomics offers boutique CRO services that leverage
its TruTumor(TM), patient-derived tumor models coupled to a wide range of
multi-omics assays (genomics, proteomics and biochemical), and an AI-powered
proprietary bioinformatics platform (“D-CHIP”) to provide a tailored solution
to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary
is developing a new rapid approach to growing tumors in the laboratory, which
essentially “fools” cancer cells into thinking they are still growing inside a
patient. Its proprietary Oncology Discovery Technology Platform kits will
assist researchers and clinicians to identify which cancer cells bind to
specific biomarkers. Once the biomarkers are identified, they can be used in
TumorGenesis’ Oncology Capture Technology Platforms, which isolate and help
categorize an individual patient’s heterogeneous tumor samples to enable the
development of patient-specific treatment options. Helomics and TumorGenesis
are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division
markets its patented and FDA-cleared STREAMWAY System, which automates the
collection, measurement and disposal of waste fluid, including blood,
irrigation fluid and others, within a medical facility, through both domestic
and international divisions. The company has achieved sales in five of the
seven continents through both direct sales and distributor partners. For more
information, visit the company’s website at www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates
relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI
About MissionIRNewsBreaks
MissionIRNewsBreaks provide
a rapid summary of corporate news that catch the attention of MissionIR. MissionIRNewsBreaks are created by
our Team of professional journalists that keep a constant eye on the markets,
these posts are designed to inform you on the latest happenings of our clients
and other publicly traded companies on our radar. From earnings, acquisitions
and agreements to conference attendance and clinical study results, our news
breaks keep you up-to-date with the day’s top movers. MissionIR is primarily
focused on strategic communications. We have executed countless communications
programs to address the needs of companies ranging from start-ups to
established industry leaders, gaining valuable experience and the expertise
necessary to determine the most effective strategy for any given situation.
Please see full terms of use and disclaimers on the Mission
Investor Relations website applicable to all content provided by MIR, wherever
published or re-published: http://www.missionir.com/disclaimer.html
